Skip to content
ALS News Today logo Newsletter
Newsletter
  • About ALS
    What is ALS?
    Causes and risk factors
    Diagnosis
    Symptoms
    • Speech problems
    • Breathing and swallowing
    • Pseudobulbar affect
    Types of ALS
    • Familial ALS
    • Sporadic ALS
    Treatments
    • Approved treatments
    • Experimental treatments
    • Non-drug treatments
  • Living with
    Living with ALS
    Mental health
    Diet
    Exercise
    Aids and adaptations
  • Community
    Columns
    • Joyful Sorrow — Kristin Neva
    • Living Well With ALS — Dagmar Munn
    • Thunder Road — Juliet Taylor
    Archived columns
    • OutSpoken — James Clingman
    • The Mighty Mind — Rachel Doboga
    In memoriam
    • Notes From the ALS Front — Rick Jobus
  • News
  • Forums
  • Resources
    Advocacy partners
  • What can we help you find today?

  • Social Clips
  • Last Week’s Top-3 Most Read Posts On ALS

Last Week’s Top-3 Most Read Posts On ALS

admin avatar

by admin | January 18, 2016

Share this article:

Share article via email
  • Share on Facebook
  • Share on Twitter
  • Share on Reddit
  • Share via Email

Read the Articles Here:

ALS Stem Cell Therapy Seen to Benefit Patients in First Round of Clinical Tests

ALS Patients Show Increased Response to Specific Receptor in Spinal Cord

ALS Severity, Duration May Be Linked to Glutamate Toxicity

 

Print This Page

Tags

glutamate, most read, stem cell therapy

Recent Posts

  • Wreath season ends; a season of being an ALS caregiver stretches on
  • Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS
  • For the new year, I choose to live in the present and move forward
  • FDA clears pivotal Phase 3 trial of new ALS oral therapy pridopidine
  • SOD1-ALS therapy Qalsody moves closer to public funding in Canada


Recommended reading

A gavel strikes a sound block in this illustration of a decision being reached.
December 18, 2025 News by Michela Luciano, PhD

Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS

banner for
December 17, 2025 Columns by Dagmar Munn

For the new year, I choose to live in the present and move forward

A stamper is seen alongside the stamp of a large check mark inside a circle.
December 17, 2025 News by Michela Luciano, PhD

FDA clears pivotal Phase 3 trial of new ALS oral therapy pridopidine

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.